291 related articles for article (PubMed ID: 37304236)
1. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
Bao W; Han Q; Guan X; Wang Z; Gu M
Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
[TBL] [Abstract][Full Text] [Related]
2. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
[TBL] [Abstract][Full Text] [Related]
3. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
[TBL] [Abstract][Full Text] [Related]
5. A novel risk signature based on liquid-liquid phase separation-related genes reveals prognostic and tumour microenvironmental features in clear cell renal cell carcinoma.
Lu Q; Xi P; Xu S; Zhang Z; Gong B; Liu J; Zhu Q; Sun T; Zhu S; Chen R
Aging (Albany NY); 2024 Mar; 16(7):6118-6134. PubMed ID: 38546385
[TBL] [Abstract][Full Text] [Related]
6. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.
Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL
Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528
[TBL] [Abstract][Full Text] [Related]
7. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma.
Ju L; Shi Y; Liu G
PeerJ; 2022; 10():e14506. PubMed ID: 36570012
[TBL] [Abstract][Full Text] [Related]
9. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
Tai R; Leng J; Li W; Wu Y; Yang J
BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
[TBL] [Abstract][Full Text] [Related]
10. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
11. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
12. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
[TBL] [Abstract][Full Text] [Related]
13. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
14. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
15. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
Gao J; Ye F; Han F; Jiang H; Zhang J
Front Immunol; 2022; 13():956679. PubMed ID: 36177018
[TBL] [Abstract][Full Text] [Related]
16. Analysis of lncRNAs profiles associated with ferroptosis can predict prognosis and immune landscape and drug sensitivity in patients with clear cell renal cell carcinoma.
Zong H; Li A; Huang Y; Che X; Zhang Y; Ma G; Zhou Z
J Biochem Mol Toxicol; 2023 Nov; 37(11):e23464. PubMed ID: 37477388
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
18. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
19. A novel ferroptosis-related 12-gene signature predicts clinical prognosis and reveals immune relevancy in clear cell renal cell carcinoma.
Hong Y; Lin M; Ou D; Huang Z; Shen P
BMC Cancer; 2021 Jul; 21(1):831. PubMed ID: 34281531
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Model for Clear-cell Renal Cell Carcinoma Based on Natural Killer Cell-related Genes.
Shi X; Yuan M; Yang Y; Wang N; Niu Y; Yang C; Dong A; Zhu H; Jia X
Clin Genitourin Cancer; 2023 Jun; 21(3):e126-e137. PubMed ID: 36513558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
